{"name":"Hansoh Pharmaceutical","slug":"hansoh","ticker":"3692.HK","exchange":"HKEX","domain":"hansoh.com","description":"Hansoh Pharmaceutical Group Company Limited is a pharmaceutical company that manufactures and sells various types of medicine in mainland China. It was founded in 1995 in Lianyungang, Jiangsu Province, China, by Zhong Huijuan, who is the company's chair. Zhong and her family own 66% of the company. It is the largest psychotropic drug producer in China.","hq":"Lianyungang, Jiangsu, China","founded":1996,"employees":"9347","ceo":"Zhong Huijuan (Chair) / Lyu Aifeng (CEO)","sector":"CNS / Oncology / Autoimmune","stockPrice":38.22,"stockChange":-1.14,"stockChangePercent":-2.9,"marketCap":"$231.4B","metrics":{"revenue":15028324352,"revenueGrowth":32,"grossMargin":89.9,"rdSpend":0,"netIncome":5555461120,"cash":31566280704,"dividendYield":1.1,"peRatio":36.1,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"Hansoh Pharmaceutical's CNS Treatment patent cliff ($1.2B at risk)","drug":"Hansoh Pharmaceutical's CNS Treatment","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"morinidazole","genericName":"morinidazole","slug":"morinidazole","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"morinidazole","genericName":"morinidazole","slug":"morinidazole","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2023-09-01","type":"regulatory","headline":"Hansoh Pharmaceutical Receives Approval for New Drug in China","summary":"Hansoh Pharmaceutical announced that it has received approval from the National Medical Products Administration (NMPA) for its new drug, which is indicated for the treatment of a specific CNS disorder.","drugName":"New Drug","sentiment":"positive"},{"date":"2022-02-22","type":"earnings","headline":"Hansoh Pharmaceutical Reports Strong Q4 2021 Earnings","summary":"Hansoh Pharmaceutical reported strong earnings for Q4 2021, driven by the success of its key products in the CNS and oncology markets.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxQYUdCcWM1WkQ4MUJwMDYwVFFaaXJPQVRqN096ako4R3o5aFB0OTB3bnJ3OURobEk1d0hQZ1R3R3M2MDdhVWNJSVAxUWFodFlZZlBLU09zd0NmUTNIZjhsRFNfNmU1cUgtYm5QanU5eTdVQmVhR0hla0tzakxwVVRQSlBuM0ZGSGJrdmlxWHdEdWx5d3o3TDRMSE5UOTBaY0pGOWp3SjV4V3liOG8xckZHenNGUjBBRG5yOTZVQm9yYlZIdXZiNVF2QnE1cHdOU0ZPZ3EwRkV1ai1fd19OeWVPb21VdzNuSnNaV2xkMnBZdnhXYU9rQ3RYc9IB_gFBVV95cUxOWTh2SWdydHZWajZscjVXTWtVRkwzMzJ4TjBBbTJSVmhLak1pNDV2QzBkdkF6LUUyaWw0WUNKTFZNQUZWbk1vaXJkTzFxNGFLY2xUd1VKVjQxSm03TV9Xb05hU1JzcE12NDJpN09Wc1YydDZ1TTJEWU9IT015UDR0bU9pMkh5eThnVDFpWHhCWmRZSkJzNVBhSkd6QldrdFp1Zmpmb3BiSXRPM0RQdGxwb3hPdWticW1iTHYwM1JsY1U0QXZ3UmllX3hfako1dDZteTZ4UG83cUpUS3lCckNpR0RtZ0ZBMDlEd1BuSDZZbjNOa25ob1pzUU1qUHlhdw?oc=5","date":"2026-03-30","type":"pipeline","source":"simplywall.st","summary":"Hansoh Pharmaceutical Group (SEHK:3692) Net Margin Strength Backs Bullish Narratives - simplywall.st","headline":"Hansoh Pharmaceutical Group (SEHK:3692) Net Margin Strength Backs Bullish Narratives","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-AFBVV95cUxOVS1KNjhad1E1bjN6RHlEMFFkN2poRHNoVHFlc3loNXlvRmhOc1RPd1hOaTUxc09DQl9wSzdraXl1TUFVTDkwcDlXV1dvQ0RseWF0bl9nbmh3RUVWeTBCeHJEajFfWk9xbkhZYUUwYi13WVdtczQ0WDUyVWlsdkxEdkh4VXVMbHlLdzNOem5iZzhqZnd0Tl9KWTZydmpvQzZCeWl3bzFhMTAwZTByVGstQVZEa1dtOXZGZlZDeFhNbUw3T3RSUVBXV3B2Q1pCWE9TblNzcUNLRTB1WXNZVl9HQUhzbnBBTlcyMWYtb3U4Z2l5UXRGOGQ1OdIB_gFBVV95cUxNWVRUMkZGMDJfV3gybTlvdEs0eHZMTlNveE9kNGZQRHV4YWM5ekJMQzVDY1dDam5Zb1hpSmNwYzZ0YkdCTFpzVzFneHJZMjFNZWVOMnZTSE9KaEJjVmlvem1oVW9LWGREekQ2aGh3Yk5kQ2JqMTFpci1iWWVVOEVCR1Z0Zi1WdWZYMlBlcmhUVHVxTy11cExlcHZxdnNOYnVrbU95eEFobG96YmpuR3dFR01FdUw5Q3J6cTlBa05ZUXhMcWtTMmp2U2lESkRkSHJESGZiX0I4V1hETWMyWnk2UG1ZUEUtTlRKbzdpMlhzRzVNWFJQTVI2UFJIVFZtdw?oc=5","date":"2026-03-01","type":"regulatory","source":"simplywall.st","summary":"Assessing Hansoh Pharmaceutical Group (SEHK:3692) Valuation After EU Approval For Aumolertinib Mesylate Tablets - simplywall.st","headline":"Assessing Hansoh Pharmaceutical Group (SEHK:3692) Valuation After EU Approval For Aumolertinib Mesylate Tablets","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMibEFVX3lxTFBVcloyUWlTN0pqbXdNTDRpMDljYXUybV82d3c0REMtbjR3WFJNZ2pocUIzZ3FDYmE1WF9RU2ZEaDJhejQ0ZDVjcXZmMEVqNFF3MWdubUpWWWcwcG1OWEFEQ081UFYwRUZEMVl4dA?oc=5","date":"2023-07-05","type":"regulatory","source":"팜뉴스","summary":"TiumBio and Hansoh Pharma Announce Clinical Trial Approval of 'HS-10518/TU2670' from NMPA in China - 팜뉴스","headline":"TiumBio and Hansoh Pharma Announce Clinical Trial Approval of 'HS-10518/TU2670' from NMPA in China - 팜뉴스","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiigJBVV95cUxNY0dtN0UxZFpJaWc2X0UtMzJ6dzc4Yl9zVzV2b2x3eWlweWxGdFNIU3RoNEZpRTVRM1hoc05aWHdyMW1XUEQyQTk5cWlrWWE4SU5DYUwwMWtkVjc1b0ZqYTBROTlxZzNMRjYwdUstbVVUM3ZMZUQ3S2xqMGpDQVhmUkhkWEM2akpYMVlMLU1mY21aLWcyekxtN1FkQUNiRDgxUm40RDFjczRReXpfNHczOGdqSXFsTHJEWXFBT2g5dnE3R1IyYnBnNFFLMEVvbjVlTktwak1ZUmpLc241VUpIb1hoNXVNUjNyckhQS0NWcU1JTDRfc0RnMmRMeXQ4NThIRDNENjhLQTBldw?oc=5","date":"2022-05-03","type":"deal","source":"Business Wire","summary":"NiKang Therapeutics and Hansoh Pharma Announce Strategic Collaboration and License Agreement for NKT2152 in Greater China - Business Wire","headline":"NiKang Therapeutics and Hansoh Pharma Announce Strategic Collaboration and License Agreement for NKT2152 in Greater Chin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxQLUZSRmptQXBva1NHdkcySmdfYjY5RF92MGllYjE4Z2p1WEhUS2xkOFFseDg1VEdnWnR5X3ZTakJxWHRya1RwNjZqaUpZM3VYY1dubFl0NFk5aVJBRVBDbGJGOEZPS1k0QWR6MWM3WEItWERENTRJeEJoWDRkODc1QTM2RjE4MTJ0ZUJ1cDVUbExqYWFlV0hwR2dvbGFpanRaWFpDRGNYMzJWdjVxSmJmN1dKaUhOTUNuWGVqd25fZ2xodlJsQTFwLWNaY1pBdzJGX3lMSHQ4N2RzSXZteUFSa2dURS1zX2RuaTRaSHdQeFA3emJXaDE0N0VQNHJmdHhrT3Nj?oc=5","date":"2021-02-17","type":"deal","source":"Business Wire","summary":"SCYNEXIS and Hansoh Pharma Announce Licensing Agreement and Strategic Partnership for Ibrexafungerp in Greater China - Business Wire","headline":"SCYNEXIS and Hansoh Pharma Announce Licensing Agreement and Strategic Partnership for Ibrexafungerp in Greater China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxQemwwSkhEVW02YzB1bjA4bU80RnZ1ZVVvRnBxeDNFd2xCbWxkaFJHMDk3NnJENlZZQ1JkQlVSbnE3RzlFMXFLUzZUSFkyRVp1dld5R3R5TW5Ha0xremdWT1Z6dGd1aUNoSlhlMGJLYzR5bzJxT0xyd202R2VtdUdZLTlxUm9sZS16ZzhqWExkVzZzRVZVS0pzR2lvcUNrVjZkWHJtLWxCWER6N21iaEt3ODdNRlNLV0V3dVcwQVFQbzZfaWpiTEpxd0ltd09YNVoxd2w1WVp4OTRyQjQ3WTRJcWNUOEdmeXhSTjdCd241bnhqRGZHN2hVWGlDMkFWclA3WEc0?oc=5","date":"2020-07-28","type":"deal","source":"Business Wire","summary":"Terns Pharmaceuticals and Hansoh Pharma Announce Collaboration and License Agreement for TRN-000632 in Greater China - Business Wire","headline":"Terns Pharmaceuticals and Hansoh Pharma Announce Collaboration and License Agreement for TRN-000632 in Greater China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_wFBVV95cUxNV2V1aFU3cFY5cUQ2MWkyX1N0VnMtTkdfMWJCelFRZUtDcndmS3JiejMxM29LNmtpbE9SX2pNYVl4bW45aFBYUlRaS1VPZTJaeFJabTNvZU9aQVY0QjBoenRDaWlvWnZaZGtkU21QQTVFT2RjRjk0RVUyanFZa1FZei02UDRHa2c5T185MEt6cVdGcko2OERHVGp2TURlXzA0NDhPa1Z0UDFYdW93TjRtS3VReDhaVWM3aEdtVmN6WWlaTzN2cmdOSVdaUFdfTGpfWmR3Q0g3S0FCZV9IMXdxY21TR055eDRmYU1kRi01QzcyUWpRMW5rS3Fpc0tJdlU?oc=5","date":"2020-07-23","type":"deal","source":"Business Wire","summary":"CORRECTING and REPLACING Hansoh Pharma Announces Strategic Collaboration and Licensing Agreement for Almonertinib - Business Wire","headline":"CORRECTING and REPLACING Hansoh Pharma Announces Strategic Collaboration and Licensing Agreement for Almonertinib","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxQdlRNTDROSGs4aVplUERJNVlvZUREdDNES1VvVVdwOEtIT2l3Z09QSVFEbVV0T3B6d3RTcmZYTENjRldqRTlPQzFqY2h6enZFSG9RYW9XQWNLWHBWVG9JaTJhdmI4RVhhUkhCSWlydVpxNkQwMHFlUElpNlNxTEZZT2F5SVliZXgwLXpVb0xxVW1sMFpmOHF2MHBXeU4tbVg0NXlzMTdYSll6WmJ1bnFISjEzaXZjbzZMc2ZKa00xNmpvb3V6RjF5RHZHeVk2ZmRHVTM1UTN1Z2tQUjBsOGZGYVlhYmhYOVRkR2NUZGpBdXdPeVhrTlZvaGE2SkFTLXp4YjFKcjRfcU5nRE5PRWJTLWVGSG1sR2pHaXhPd1hRdy1IZFhDWDhaTmJEa25PRFVUS2c?oc=5","date":"2020-04-23","type":"deal","source":"Business Wire","summary":"Hansoh Pharma and NiKang Therapeutics Enter into a Development and Commercialization Partnership for a Novel Treatment for Anti-Viral Diseases in China - Business Wire","headline":"Hansoh Pharma and NiKang Therapeutics Enter into a Development and Commercialization Partnership for a Novel Treatment f","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxPVTRFcUVIYXZlUUk1aU00V04zY3NsbEhqemoyY3pWUl9jTkJQTVNkU1ZpRlJfbC15UHdIeU1CMmdxWWYwVjVOT2hCYm14NUpQWVNXRmhXM0h0bDFBRHFsa21ac2VRRHZXMnE1REVqdGZnMUxqaTZxTDF5UTFhY0RsX2NuVlVlX21LUjI5dEp3Y3ZYUFNCMzdSR3BEb2ZSUQ?oc=5","date":"2019-06-14","type":"pipeline","source":"hkex.com.hk","summary":"HANSOH PHARMACEUTICAL GROUP CO. LTD. (3692) - hkex.com.hk","headline":"HANSOH PHARMACEUTICAL GROUP CO. LTD. (3692)","sentiment":"neutral"}],"patents":[{"drugName":"Hansoh Pharmaceutical's CNS Treatment","drugSlug":"generic-name","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US","annualRevenue":1200000000}],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["BeiGene","Innovent Biologics","Zai Lab"],"therapeuticFocus":["CNS","Oncology"],"financials":null,"yahoo":{"currentPrice":38.22,"previousClose":39.36,"fiftyTwoWeekHigh":44.22,"fiftyTwoWeekLow":19.82,"fiftyTwoWeekRange":"19.82 - 44.22","fiftyDayAverage":35.3,"twoHundredDayAverage":36.41,"beta":0.53,"enterpriseValue":204228526080,"forwardPE":31.2,"priceToBook":5.68,"priceToSales":15.4,"enterpriseToRevenue":13.59,"enterpriseToEbitda":35.35,"pegRatio":0,"ebitda":5776870912,"ebitdaMargin":38.4,"freeCashflow":0,"operatingCashflow":0,"totalDebt":105093000,"debtToEquity":0.3,"currentRatio":8.09,"returnOnAssets":9.4,"returnOnEquity":17.3,"analystRating":"1.4 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":22,"targetMeanPrice":46.32,"targetHighPrice":52.33,"targetLowPrice":38.42,"dividendRate":0.43,"payoutRatio":0.36,"fiveYearAvgDividendYield":0,"exDividendDate":1783036800,"insiderHeldPercent":79.7,"institutionHeldPercent":10.1,"sharesOutstanding":6053955423,"floatShares":1216592437,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":1.06,"epsForward":1.23,"revenuePerShare":2.52,"bookValue":6.73,"officers":[{"age":63,"name":"Ms. Huijuan  Zhong","title":"Founder, Chairlady & CEO"},{"age":47,"name":"Dr. Aifeng  Lyu","title":"Executive Director"},{"age":38,"name":"Ms. Yuan  Sun","title":"Executive Director"},{"age":48,"name":"Mr. Min  Hu","title":"Chief Financial Officer"},{"age":55,"name":"Dr. Shan  Jiang","title":"Chief Technology Officer"},{"age":65,"name":"Dr. Chih-Hung  Lee","title":"Chief Science Officer"},{"age":61,"name":"Mr. Chuanhe  Xu","title":"Senior Vice President"},{"age":54,"name":"Dr. Weiyong  Sun","title":"Chief Business Officer"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.hspharm.com","phone":"86 40 0828 5227"}}